Friday, March 3, 2023
This conference has already taken place.
Description
Cardiac sarcoidosis is a rare autoimmune disorder that causes cells to clump together into granulomas that disrupt heart function. It's a variation of sarcoidosis. Cardiac sarcoidosis can mimic other conditions and go undiagnosed for years. As a result, there is a gap in knowledge when selecting medications, testing modalities, especially the use of imaging, completing physical assessments and risk stratification, when to refer patients, utilization of current treatment strategies and clinical trials for this condition. This symposium is available for in-person and online participation.
Dates and Times
Start: 3/3/2023 8:00 AM
End: 3/3/2023 12:00 PM
Objectives
At the conclusion of this activity, participants should be able to:
1. Recognize the role of PET and MRI for diagnosis of cardiac sarcoidosis.
2. Review the role serum biomarkers for the diagnosis of cardiac sarcoidosis.
3. Identify the role of prolonged ambulatory rhythm monitoring for cardiac sarcoidosis.
4. Discuss risk stratification for pacing and defibrillation therapy.
5. Explain the role of immunosuppressants for the treatment of cardiac sarcoidosis.
6. Describe the management of ventricular arrhythmia in patients with cardiac sarcoidosis.
7. Review surveillance for long-term complications of cardiac sarcoidosis.
8. Discuss the association of cardiac sarcoidosis and advanced heart failure and pulmonary hypertension.
9. Describe the multidisciplinary approach for management of cardiac sarcoidosis.
Agenda
Session 1: Diagnostic Evaluation of Cardiac sarcoidosis -Moderator
Moderator: Ayesha Hasan, MD
8:00 am Multidisciplinary approach for management of cardiac sarcoidosis
Ayesha Hasan, MD
8:10 When do you suspect and refer for evaluation of cardiac sarcoidosis
Arindam Singha, MD
8:25 Clinical use of PET during diagnosis and treatment: Clinician’s perspective
Vaiibhav Patel, MD
8:40 Clinically useful lab test for diagnosis/surveillance of cardiac sarcoidosis
Elliott Crouser, MD
8:55 Q & A
Session 2: Risk stratification in Cardiac Sarcoidosis
Moderator: Steven Kalbfleisch, MD
9:05 Role of cardiac MRI for diagnosis and risk stratification of cardiac sarcoidosis – an Imager’s perspective
Karolina Zareba, MD
9:20 Implications of finding high burden PVCs, NSVT or atrial arrhythmias during ambulatory monitoring.
Jordana Kron, MD
9:35 Risk stratification - Determining who with cardiac sarcoid requires device therapy
Steven Kalbfleisch, MD
9:50 Q & A
Session 3: Surveillance/ Clinical follow-up
Moderator: Elliot Crouser, MD
10:00 Non-cardiac sarcoidosis: What a cardiologist needs to know? who should do this?
Eli Homsy, MD
10:15 Sarcoid trials – Purpose / importance of the trials, CHASM trial update
David Birnie, MD
10:30 Role of arrhythmia monitoring during cardiac sarcoidosis during follow up
Muhammad Afzal, MD
10:45 Q & A
Session 4: Clinical management of complications of cardiac sarcoidosis
Moderator: Rami Kahwash, MD
11:00 Management of HF in cardiac sarcoidosis
Gaurang Vaidya, MD
11:15 Role of immunosuppressants for treatment of arrhythmias in cardiac sarcoidosis
Rami Kahwash, MD
11:30 Management of sustained VT: immunosuppressant vs AADx vs catheter ablation vs sympathectomy:/SBRT
Toshimasa Okabe MD
11:45 Q & A
11:55 Closing Remarks
Steven Kalbfleisch, MD
Pricing
Tier | Price |
---|---|
Physician, participating in person | $0.00 |
Physician, participating online | $0.00 |
Nurse/Nurse Practitioner, participating in person | $0.00 |
Nurse/Nurse Practitioner, participating online | $0.00 |
Allied Medical Professional, participating in person | $0.00 |
Allied Medical Professional, participating online | $0.00 |
Other, participating in person | $0.00 |
Other, participating online | $0.00 |
Speakers
Location
The Ohio State University Wexmer Medical Center
Biomedical Research Tower
460 W. 12th AVenue
Columbus, OH 43210
Accreditation Statement
The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The Ohio State University designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.